Feb 4, 2025
November 2024 ? [New Jersey, United States] ? Axela Biosciences proudly announces its formation through the strategic merger of Nanobiotec (PicoImmune) and Emerther, uniting expertise in preclinical services, wet lab consumables, and in vitro diagnostic solutions under one entity.
Nanobiotec (PicoImmune) has been a leader in preclinical bioassays, biomarker discovery, and immunology research, providing contract research solutions to biotech and pharmaceutical companies. Meanwhile, Emerther has specialized in wet lab consumables, sample collection kits, and in vitro diagnostic tools, supporting translational research and clinical applications.
This merger enhances Axela Biosciences? ability to streamline preclinical research and diagnostic assay development, offering end-to-end solutions from assay design and validation to sample processing and biomarker analysis. With CLIA-certified capabilities, Axela Biosciences is well-positioned to support biotech, pharma, and clinical partners in accelerating research and diagnostics.
"Bringing together the strengths of Nanobiotec (PicoImmune) and Emerther allows us to provide comprehensive, high-quality solutions that bridge the gap between research and clinical application," said Maggie Li, CEO of Axela Biosciences. "We are committed to advancing innovation in preclinical and diagnostic science with a focus on precision, efficiency, and reliability."
For more information about Axela Biosciences and its expanded capabilities, visit Axelabio.com or contact david.huang@axelabio.com.
Company:
View Axela Biosciences's profile
Links:
